Copenhagen posts

Feed

Cramer on BloggingStocks: Obama's pro-coal stance makes Copenhagen a charade

TheStreet.com's Jim Cramer says the biggest companies can lobby their way to huge profits.

Anyone serious about climate change knows that coal is the worst enemy of the environment. We can have all of the electric cars we want, if they are hooked into a coal-based utility system then the gains are irrelevant. We can also be sure that while all sorts of companies, like the General Electrics (GE) (Cramer's Take) and Cokes (KO) (Cramer's Take) and Nikes (NKE) (Cramer's Take) and Nestles, support climate control, they are not equal to one Southern Company (SO) (Cramer's Take), which is an important coal-burning company and a huge lobbyist for the coal industry.

Our nation has a two-pronged climate philosophy: pushes on conservation and on renewables. Neither is enough to get us through the next 10 years; we can't produce enough renewable energy at a cheap price and we can't caulk our way out of the jam.

Continue reading Cramer on BloggingStocks: Obama's pro-coal stance makes Copenhagen a charade

Altria may be in talks with UST, smokeless tobacco maker

The New York Times reports that Altria Group (NYSE: MO) "is in advanced talks to buy UST (NYSE: UST), the maker of the popular Skoal and Copenhagen smokeless tobacco brands, for more than $10 billion." Investors are reacting positively to the news, sending Altria shares over 1% higher.

Since spinning off Philip Morris International (NYSE: PMI) in March, Altria expected to experience sales decline. U.S. cigarette industry has been on the decline for years and Phillip Morris USA indeed saw an adjusted 3.6% drop in sales last year. The company has projected the trend will continue and cigarette sales volume to fall between 2.5% to 3% in the U.S. over the next few years. The reasons are knows: concerns about health, smoking bans and price increases. Altria has tried and failed to create its Marlboro brand smokeless tobacco products and has also pulled the plug on Marlboro Ultra Smooth, which despite using better filters didn't see higher consumer acceptance.

Continue reading Altria may be in talks with UST, smokeless tobacco maker

UST Inc. (UST): Something to chew on?

A wise investor never lets a perceived vice get between him and a nice profit. So no matter how you feel personally about booze and chewin' tobacco, read on.

Goldman Sachs just issued a report today upgrading UST Inc. (NYSE: UST) to a BUY. UST Inc is a holding company not just for U.S. Smokeless Tobacco Company, which makes smokeless tobacco products (that's chaw to you and me) under the Copenhagen and Skoal brand names, but also for the wine brand, Ste. Michelle Wine Estates, that produces wine under the Chateau Ste. Michelle and Columbia Crest (contributing 15% of total sales).

Sold mainly in the U.S., this is an example of a company that some people don't necessarily feel comfortable supporting -- booze and chewing tobacco. But if this doesn't offend your sensibilities, the company presents a strong buy opportunity. As Goldman's report states, the market is overestimating the level of competition -- particularly from Marlboro --in smokeless tobacco, where UST makes the majority of its profit.


Continue reading UST Inc. (UST): Something to chew on?

Option update: UST has competition from Altria (MO)

UST (NYSE: UST) volatility Flat; UST down 6%; Altria Group (NYSE: MO) testing Marlboro Moist Smokeless tobacco. UST, a leading producer and marketer of moist smokeless tobacco products (Skoal, Copenhagen), is recently down $3.06 to $48.91. MO announced the introduction of Marlboro Moist Smokeless tobacco into test market. MO had been frequently mentioned as possibly interested in UST. UST has a market cap of $7.7 billion with quarterly March 2007 total revenue of $447 million. UST September option implied volatility of 26 is near its 26-week average of 23 according to Track Data, suggesting non-directional price risk.

Forest Labs (NYSE: FRX) volatility Elevated on patent challenge Appeal. FRX, a U.S. based pharmaceutical company, is recently down .48 to $37.74. FRX's Lexapro, an antidepressant accounting for 66% of FRX total revenue, is facing a patent challenge appeal.Buckingham Research says "LXP patent challenge appeal which we would expect to be resolved from an appellate decision over the next few months (we expect FRX to prevail in this case)." FRX call option volume of 9,195 contracts compares to put volume of 4,571 contracts. FRX September option implied volatility of 70 is above its 26-week average of 33 according to Track Data, suggesting larger price risks.

Daily options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.

Symbol Lookup
IndexesChangePrice
DJIA-89.2312,801.23
NASDAQ-23.352,903.88
S&P 500-9.311,342.64

Last updated: February 11, 2012: 12:04 PM

Hot Stocks

General Electric

18.875-0.255(-1.33)

Alcoa

10.29-0.35(-3.29)

Apple Inc

493.42+0.25(+0.05)

Google Inc 'A'

605.91-5.55(-0.91)

Bank of America

8.07-0.11(-1.34)

Wal-Mart Stores

61.90-0.06(-0.10)

Exxon Mobil Corp

83.80-1.08(-1.27)

Ford

12.44-0.25(-1.97)

Citigroup

32.925-0.735(-2.18)

IBM

192.42-0.71(-0.37)

Yahoo

16.14+0.14(+0.88)

Starbucks

48.82-0.38(-0.77)

Microsoft

30.495-0.275(-0.89)

Home Depot

45.33+0.06(+0.13)

DailyFinance Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

Page Loaded in 1328979881443 ms.